Drug intelligence / Profile preview

LY-2300559

Development stage: Discontinued
Lead developer: Eli Lilly
Modality: Small Molecules
Administration: Oral

Overview

LY-2300559 is a small molecule drug that was developed by Eli Lilly for the prevention of migraine. It acts as a dual modulator, functioning as a positive allosteric modulator of metabotropic glutamate receptor 2 (mGluR2) and an antagonist of cysteinyl leukotriene receptor 1 (CysLTR1). The drug reached phase II clinical trials for migraine prevention but its development has since been discontinued. Its mechanism involves modulation of neurotransmission and inflammatory pathways relevant to migraine pathophysiology[1][3][4][5].

Other names: Benzoic acid, 3-((S)-(4-((4-acetyl-3-hydroxy-2-propylphenoxy)methyl)phenyl)hydroxymethyl)-

Targets

CYSLTR1 (Cysteinyl-leukotriene type 1 receptor)GRM2 (mGluR2)

Beyond the preview

Go deeper on LY-2300559.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LY-2300559.

Explore the full profile